Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial

Lancet

Volumn 362, Issue 9391, 2003, Pages 1171-1177

  Taha, Taha E ^a   Kumwenda, Newton I ^a   Gibbons, Amanda ^a   Broadhead, Robin L ^b   Fiscus, Susan ^c   Lema, Valentino ^b   Liomba, George ^b   Nkhoma, Chiwawa ^d   Miotti, Paolo G ^e   Hoover, Donald R ^f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MALAWI   (Malawi)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MORTALITY; MOTHER CHILD RELATION; MULTICENTER STUDY; NEWBORN; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEVENS JOHNSON SYNDROME; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0141987840     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14538-2     Document Type: Article

References (21)

1. Wiktor S.Z., Ekpini E., Karon J.M., et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 353:1999;781-785.
2. Dabis F., Msellati P., Meda N., et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 353:1999;786-792.
3. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo controlled trial. Lancet. 359:2002;1178-1186.
4. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 354:1999;795-802.
5. Owor M, Deseyve M, Duefield C. The one year safety and efficacy data of the HIVNET 012 trial. Abstract LbOr1, XIIIth International AIDS Conference, July 9-14, 2000, Durban, South Africa.
6. Mirochnick M, Dorenbaum A, Blanchard S, et al. Pre-dose infant nevirapine (NVP) concentration with the 2-dose intrapartum-infant NVP regimen. 3rd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. September 9-, 2001; Kampala, Uganda (Abstr 101).
7. Van Rombay K.K.A., Otsyula M.G., Marthas M.L., Miller C., McChesney M.B., Pedersen N.C. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 39:1995;125-131.
8. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 44:1995;929-933.
9. Wade N.A., Birkhead G.S., Warren B.L., et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 339:1998;1409-1414.
10. Biggar R.J., Miley W., Miotti P.G., et al. Blood collection on filter paper: a practical approach to sample collection for studies of perinatal HIV transmission. J Acquir Immune Defic Syndr. 14:1997;368-373.
11. Taha T.E., Kumwenda N., Gibbons A., et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS. 16:2002;851-858.
12. Rice J.A. Mathematical statistics and data analysis. 2nd edn: 1995;Duxbury Press, Belmont (CA).
13. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 47:1998;22-23.
14. Moodley D., Moodley J., Coovadia H., et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type I. J Infect Dis. 187:2003;725-735.
15. Nolan M., Fowler M.G., Mofenson L.M. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr. 30:2002;216-229.
16. Eshleman S.H., Mracna M., Guay L.A., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 15:2001;1951-1957.
17. Biggar R.J., Miotti P.G., Taha T.E., et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet. 347:1996;1647-1650.
18. Semba R.D., Kumwenda N., Hoover D.R., et al. Human immunodeficiency virus load in breastmilk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 180:1999;93-98.
19. Biggar R.J., Mtimavalye L., Justesen A., et al. Does umbilical cord blood polymerase chain reaction positivity indicate in utero (pre-labor) HIV infection? AIDS. 11:1997;1375-1382.
20. Boehringer Ingelheim. Investigator's Brochure, Nevirapine (BI-RG-587) Viramune. Version 6. Ingelheim Pharmaceuticals, Randberg. March, 2000.
21. Leroy V., Karon J.M., Alioum A., et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 16:2002;631-641.